BIOSYNEX (EPA:ALBIO) | Finanzwire

Basculer en Français

8295	Companies
114833	Keywords
55274	Articles
62430	Press releases

Home
Companies
BIOSYNEX

BRIEF

published on 11/04/2024 at 18:05, 16 days 16 hours ago

BIOSYNEX SA: Declaration of Shares and Voting Rights

Voting Rights Actions Transparency Financial Markets BIOSYNEX
BRIEF

published on 10/23/2024 at 18:05, 28 days 16 hours ago

Chembio Diagnostics wins grant for new syphilis test

BIOSYNEX Chembio Diagnostics Congenital Syphilis Rapid Diagnosis Gates Foundation Grant
PRESS RELEASE

published on 10/23/2024 at 18:00, 28 days 16 hours ago

BIOSYNEX SA: CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY
Chembio Diagnostics Inc., a subsidiary of BIOSYNEX, receives a grant to develop a rapid point-of-care diagnostic test for congenital syphilis supported by the Bill & Melinda Gates Foundation

Grant BIOSYNEX Congenital Syphilis Chembio Diagnostics Inc. Bill & Melinda Gates Foundation
BRIEF

published on 10/17/2024 at 18:05, 1 month 3 days ago

BIOSYNEX SA: 2024 Half-Year Results and Debt Restructuring

Revenue Growth Half-year Results Debt Restructuring Cost Rationalization American Expansions
BRIEF

published on 07/18/2024 at 18:05, 4 months 2 days ago

BIOSYNEX: Revenue for the first half of 2024 up 26%

Acquisitions Growth Turnover Export American Subsidiaries
BRIEF

published on 05/28/2024 at 17:50, 5 months 23 days ago

BIOSYNEX obtains its first CE markings according to the new IVDR regulations

In Vitro Diagnostics BIOSYNEX IVDR CE Marking Rapid Tests
BRIEF

published on 05/28/2024 at 17:50, 5 months 23 days ago

BIOSYNEX Obtains Its First CE Markings According to IVDR Regulations

BIOSYNEX IVDR CE Marking Rapid Tests Molecular Biology
BRIEF

published on 05/13/2024 at 20:22, 6 months 7 days ago

BIOSYNEX strengthens its governance and promotes new talents

Governance Chief Operating Officer ESG BIOSYNEX Health Diagnosis
BRIEF

published on 05/13/2024 at 18:05, 6 months 7 days ago

BIOSYNEX SA strengthens its governance with new appointments

Governance Appointments ESG Health BIOSYNEX
BRIEF

published on 05/03/2024 at 18:05, 6 months 17 days ago

BIOSYNEX announces its capital indicators for April 2024

Share Capital Voting Rights Financial Regulation BIOSYNEX Markets Financial Regulation

Accesswire

Published on 11/21/2024 at 10:03, 46 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 49 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 49 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 14 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 24 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:30, 19 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 44 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 46 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 49 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 49 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 51 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 29 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 17 hours 4 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 17 hours 4 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 3 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE